Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Maria Diez-Campelo, Elizabeth Esterberg, Ravi K. Goyal, Mrudula B. Glassberg, Aylin Yucel, Julien Rombi, Keith L. Davis, Maria Jimenez, Dimana Miteva, Ahmed Hnoosh, Ulrich Germing

Blood (2024) 144 (Supplement 1): 5055.

https://doi.org/10.1182/blood-2024-206948

Published: 2024

Journal Articles

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Francesco Passamonti, Rohan C. Parikh, Siddhi Korgaonkar, Manoj Chevli, Samantha Slaff, Julien Rombi, Basirat Adeyemi, Keith L. Davis, Aylin Yucel

Blood (2023) 142 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2023-173420

Published: 2023

Journal Articles

Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2021) 138 (Supplement 1): 3528.

https://doi.org/10.1182/blood-2021-149327

Published: 2021

Journal Articles

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)

Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers EM Patten, Bastian von Tresckow, Sonali M. Smith, Ana Isabel Jiminez Ubieto, Keith L. Davis, Saurabh P Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link

Blood (2021) 138 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2021-145870

Published: 2021

Journal Articles

Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Francesco Passamonti, Florian H. Heidel, MD, Rohan C. Parikh, Derek Tang, Betsy J. Lahue, Jose Alberto Nadal, Keith L. Davis, Mayank Ajmera, Arianna Kee, Pranav Abraham

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-136673

Published: 2020

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Ravi K Goyal, MS, Saurabh P Nagar, MS, Shaum M Kabadi, PhD MPH, Keith L Davis, MA, Hannah Le, PharmD, MPH, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 796.

https://doi.org/10.1182/blood-2019-122842

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Shaum M Kabadi, PhD MPH, Ravi K Goyal, MS, Saurabh P Nagar, MS, Keith L Davis, MA, Hannah Le, PharmD, MPH, Xianglin L Du, MB, MS, PhD, Preetesh Jain, MBBS,MDDM,PhD, Michael L. Wang, MD, Jorge Enrique Romaguera, MD, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 63.

https://doi.org/10.1182/blood-2019-122841

Published: 2019

Journal Articles

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Jing Xie, Alan Yong, Catherine Waweru, PhD, Thuy Anh Sorof, Ravi K Goyal, MS, Keith L Davis, MA, George Follows, Peter Hillmen, MD PhD

Blood (2019) 134 (Supplement_1): 5885.

https://doi.org/10.1182/blood-2019-123025

Published: 2019

Journal Articles

Treatment Patterns, Adverse Events, and Economic Burden in a Privately Insured Population of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia in the United States

Shaum Kabadi, PhD MPH, Ravi K Goyal, MS, Saurabh P Nagar, James A Kaye, MD, Keith L Davis, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 3557.

https://doi.org/10.1182/blood-2018-99-114735

Published: 2018

Journal Articles

Real-World Clinical Outcomes By Cytogenetic Risk Category in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France

Huamao Mark Lin, PhD, Keith L Davis, MA, James A. Kaye, MD DrPH, Katarina Luptakova, Lu Gao, PhD(candidate), Saurabh Nagar, MS, Brian Seal, RPh, MBA, PhD, Mohamad Mohty, MD PhD

Blood (2016) 128 (22): 4784.

https://doi.org/10.1182/blood.V128.22.4784.4784

Published: 2016

Journal Articles

Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France

Huamao Mark Lin, PhD, Keith L Davis, MA, James A. Kaye, MD DrPH, Katarina Luptakova, Lu Gao, PhD(candidate), Saurabh Nagar, MS, Brian Seal, RPh, MBA, PhD, Mohamad Mohty, MD PhD

Blood (2016) 128 (22): 5945.

https://doi.org/10.1182/blood.V128.22.5945.5945

Published: 2016

Journal Articles

Real-World Treatment Patterns in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in the United Kingdom

Huamao Mark Lin, PhD, Keith L Davis, MA, James A. Kaye, MD DrPH, Katarina Luptakova, Saurabh Nagar, MS, Brian Seal, RPh, MBA, PhD

Blood (2016) 128 (22): 5947.

https://doi.org/10.1182/blood.V128.22.5947.5947

Published: 2016

Journal Articles

Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib

Keith L Davis, MA, James A. Kaye, MD DrPH, Isabelle Cote, PhD, Haitao Gao, Julian Perez Ronco, MD, Raafat Seifeldin, Pharm D, MS, PhD, Estella Mendelson, BSRN, MBA

Blood (2014) 124 (21): 1857.

https://doi.org/10.1182/blood.V124.21.1857.1857

Published: 2014

Journal Articles

Increased Incidence of Thromboembolic Event Rates in Patients Diagnosed with Polycythemia Vera: Results from an Observational Cohort Study

Ravi K Goyal, MS, BPharm, Keith L Davis, MA, Isabelle Cote, PhD, Nadjat Mounedji, MD, James A. Kaye, MD DrPH

Blood (2014) 124 (21): 4840.

https://doi.org/10.1182/blood.V124.21.4840.4840

Published: 2014

Journal Articles

Comorbidity Burden in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Keith L Davis, MA, Gregory L Price, MPH, Sudeep Karve, PhD, Gerhardt M Pohl, PhD, Richard A Walgren, MD, PhD

Blood (2012) 120 (21): 1734.

https://doi.org/10.1182/blood.V120.21.1734.1734

Published: 2012

Journal Articles

Health Care Utilization and Associated Costs in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Sudeep Karve, PhD, Gregory L Price, MPH, Keith L Davis, MA, Gerhardt M Pohl, PhD, Richard A Walgren, MD, PhD

Blood (2012) 120 (21): 4273.

https://doi.org/10.1182/blood.V120.21.4273.4273

Published: 2012

Journal Articles

Survival Patterns in Patients with Non-CML Myeloproliferative Neoplasms: Evidence From a United States SEER/Medicare Population

Gregory L. Price, MPH, Keith L Davis, MA, Sudeep Karve, PhD, Gerhardt M Pohl, PhD, Richard A Walgren, MD, PhD

Blood (2012) 120 (21): 428.

https://doi.org/10.1182/blood.V120.21.428.428

Published: 2012

Journal Articles

Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Juliana Leah Meyers, MA, Yanni F Yu, Keith L Davis

Blood (2011) 118 (21): 505.

https://doi.org/10.1182/blood.V118.21.505.505

Published: 2011

NARROW

Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma

A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL)

Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Treatment Patterns, Adverse Events, and Economic Burden in a Privately Insured Population of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia in the United States

Real-World Clinical Outcomes By Cytogenetic Risk Category in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France

Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France

Real-World Treatment Patterns in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in the United Kingdom

Real-World Assessment of Clinical Outcomes in Lower-Risk Myelofibrosis Patients Receiving Treatment with Ruxolitinib

Increased Incidence of Thromboembolic Event Rates in Patients Diagnosed with Polycythemia Vera: Results from an Observational Cohort Study

Comorbidity Burden in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Health Care Utilization and Associated Costs in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Survival Patterns in Patients with Non-CML Myeloproliferative Neoplasms: Evidence From a United States SEER/Medicare Population

Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only